Metabolic Disorders
Metabolic Disorders
Advertisement
Lauren Dembeck, PhDObesity | July 16, 2025
Amycretin shows significant weight loss and tolerability in early trial, supporting further study for obesity treatment.
Brandon TwyfordObesity | July 14, 2025
ADA’s new clinical guidelines aim to eliminate weight stigma and bias in obesity care across US healthcare settings.
Alex McDonald, MD, CAQSM, FAAFPObesity | July 10, 2025
Evidence-based tips on GLP-1s, nutrition, exercise, and mindset to support sustainable weight loss and better health.
Anthony M. Auriemma, MDObesity | July 3, 2025
Personalized obesity care combining medication and lifestyle delivers better, longer-lasting weight loss and health outcomes.
Johnny HawkinsObesity | June 30, 2025
When diet and exercise wave the white flag, real medicine rolls in like the superhero with a prescription pad!
Alex McDonald, MD, CAQSM, FAAFPObesity | July 10, 2025
Dr. Alex McDonald and Dr. Regina Ragasa explore obesity’s health impact and a multifaceted approach for effective care.
Brandon TwyfordObesity | June 27, 2025
Orforglipron, a daily oral GLP-1 pill, matches Ozempic in Phase 3 trial, offering a needle-free option for Type 2 diabetes.
Lauren Dembeck, PhDType 2 Diabetes | June 25, 2025
Lifestyle and metformin interventions cut diabetes risk for 21 years in adults with prediabetes, DPP study shows.
Lauren Dembeck, PhDObesity | June 24, 2025
Black youth with dysglycemia show reduced insulin clearance, possibly contributing to β-cell dysfunction and ...
Victoria SochaType 2 Diabetes | June 20, 2025
Tirzepatide linked to reduced muscle fat infiltration and volume in type 2 diabetes, per SURPASS-3 MRI substudy findings.
Lauren Dembeck, PhDObesity | June 19, 2025
Real-world weight loss with semaglutide or tirzepatide is lower due to early discontinuation and low maintenance dosing.
Victoria SochaDiabetes | June 17, 2025
Chronic hyperglycemia in pediatric type 1 diabetes may impair white matter development; brain changes persist into puberty.
Victoria SochaObesity | June 17, 2025
Nearly half of U.S. patients discontinued semaglutide within 5 months, with cost a key barrier to continued use.
DocWire News EditorsObesity | June 19, 2025
How many medications are FDA-approved for the long-term use of treating obesity?
DT WalshObesity | June 13, 2025
Habits collapsed, health's calling 'Mayday'! The doc soars in ... time to dose the FDA way!
Anthony M. Auriemma, MDObesity | June 24, 2025
Obesity care must be evidence-based and patient-centered, says Dr. Auriemma in this call for science-driven treatment.
Leah LawrenceObesity | June 13, 2025
Obesity is a chronic, complex disease driven by biology, not just behavior—effective care requires empathy and support.
Jordana JampelMetabolic Disorders | May 15, 2025
There was also an association with higher educational levels and odds of poor sleep quality.
Jordana JampelDiabetes | May 15, 2025
Higher HbA1c levels were a higher risk factor in children with lower BMIs.
Damiana Chiavolini, PhDObesity | June 16, 2025
A new study investigated the effects of physical training on aging in the skeletal muscle of people with obesity.
Advertisement